Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$9.24 USD

9.24
604,520

+0.33 (3.70%)

Updated May 27, 2022 04:00 PM ET

After-Market: $9.23 -0.01 (-0.11%) 6:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (148 out of 253)

Industry: Medical - Drugs

Trades from $1

Zacks News

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance's (TBPH) Hypotension Study Misses Primary Goal

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

    Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

    Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

    Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

    Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

    Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

    Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

    Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet

    The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

    Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

    Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

    CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

    CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

    Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

    Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

    Zacks.com featured highlights include Theravance Biopharma, PattersonUTI Energy and Select Energy Services

    Theravance Biopharma, PattersonUTI Energy and Select Energy Services are included in this blog.

    Tirthankar Chakraborty headshot

    3 Best Stocks to Buy Right Away for Earnings Acceleration

    Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.

    Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

    Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

    Lannett (LCI) Reports Q2 Loss, Misses Revenue Estimates

    Lannett (LCI) delivered earnings and revenue surprises of -21.88% and 14.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Implied Volatility Surging for Theravance Biopharma (TBPH) Stock Options

    Investors need to pay close attention to Theravance Biopharma (TBPH) stock based on the movements in the options market lately.

    Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

    Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

    Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of 20.00% and -2.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know

    Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

    The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Kinjel Shah headshot

    Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

    AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

    Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

    Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.